Overall, the composition of GBMs nowadays differs greatly from earlier ones in that all IDH-mutant astrocytomas are excluded, and a large number of WHO grade 2-3 IDH-wildtype gliomas with specific molecular features are involved (14). The gene discussed is IDH1; the disease is central nervous system cancer.